SLN
Silence Therapeutics plc
Next earnings Aug 6, 2026
Last earnings -5.6% on 2026-05-07
$10.14
▲ +1.40%$10.14▲ +75.74%
over 1Y
L $4.30EODHDH $10.14
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+1.4%
1W+34.7%
1M+49.1%
3M+105.7%
YTD+64.9%
1Y+75.7%
Avoid
Conviction
Horizon
Medium (3–12mo)
Revenue fell -98.7% YoY.
Revenue (FY2025) $559K · FY2025
Silence Therapeutics plc shows $559K in FY2025 revenue (-98.7% YoY), a -15851.9% net margin, and -142.2% ROE.
Financials · annual, by fiscal year
| Line item | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|
| Revenue | $21.7M | $31.6M | $43.3M | $559K |
| Gross profit | $8.19M | $18.8M | $31.4M | $344K |
| Operating income | -$61.0M | -$64.4M | -$63.3M | -$91.1M |
| Net income | -$50.3M | -$54.2M | -$45.3M | -$88.6M |
| Diluted EPS | -$0.52 | -$0.49 | -$0.33 | -$0.63 |
| Net margin | -232.4% | -171.4% | -104.7% | -15851.9% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$1.43B
EV / EBITDA—
EV / Sales2550.2
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-6.2%
FCF yield-4.3%
Quality & risk
ROIC (est.)-115.5%
Free cash flow-$62.3M
Total debt—
Net cash$11.3M
Altman Z-Score5.15 safe
Piotroski F-Score1/8
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY+0.0%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsRed flag in recent filings — agreement terminated (2026-05-18). Worth a closer look.
Recent filings
all on EDGAR ↗8-KPeriod ending 2026-06-232026-06-23open ↗8-KPeriod ending 2026-06-162026-06-16open ↗8-KPeriod ending 2026-06-112026-06-11open ↗EFFECTFiling2026-05-27open ↗424B5Filing2026-05-27open ↗8-KPeriod ending 2026-05-182026-05-18open ↗S-3Filing2026-05-18open ↗10-QPeriod ending 2026-03-312026-05-07open ↗8-KPeriod ending 2026-05-072026-05-07open ↗ARSPeriod ending 2025-12-312026-04-29open ↗DEF 14APeriod ending 2026-06-162026-04-29open ↗S-8Filing2026-03-05open ↗
Frequently asked
- Is Silence Therapeutics plc (SLN) a buy?
- SLN currently carries a Avoid rating with 4/5 conviction, derived from its latest SEC filings. Revenue fell -98.7% YoY.
- What is Silence Therapeutics plc's quality score?
- SLN scores 29.039215686274506/100 (grade F) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001479615, latest 10-Q filed 2026-05-07) · EODHD · as of 6/26/2026, 6:12:11 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.